To evaluate the humeral head bone volume of patients with cuff tear arthropathy (CTA) and examine the therapeutic effect of zoledronate in a rat modified model of CTA (mCTA). The bone mass in patients with CTA was measured using Hounsfield units from CT images. The mCTA was induced by transecting the rotator cuff, biceps brachii tendon, and superior half of the joint capsule in adult rat shoulders. A single subcutaneous injection of zoledronate was followed by bone histomorphometry and immunohistochemistry of the humeral head, as well as the Murine Shoulder Arthritis Score (MSAS) assessment. The humeral head bone volume was decreased in patients with CTA. In the mCTA model, M1 macrophages were increased in the synovium and were decreased by zoledronate treatment. The increased expressions of TNF-α, IL-1β and IL-6 in mCTA synovium and articular cartilage were suppressed in the zoledronate-treated mCTA group. The expression of catabolic enzymes in the articular cartilage and MSAS showed similar results. The zoledronate-treated mCTA group showed a decreased subchondral bone collapse with a decreased RANKL/OPG expression ratio and a suppressed number of osteoclasts compared with the control mCTA group. The enhanced expressions of HMGB1 and S100A9 in the mCTA shoulders were eliminated in the zoledronate-treated mCTA group. The humeral head subchondral bone was decreased in patients with CTA. In the mCTA model, the collapse and osteoarthritic changes were prevented by zoledronate administration. Zoledronate seemed to suppress the number of M1 macrophages in the synovium and osteoclasts in the subchondral bone.

中文翻译：

---

唑来膦酸盐减轻肩袖撕裂关节病大鼠模型中的软骨下骨塌陷和关节软骨变性


评估袖带撕裂关节病 (CTA) 患者的肱骨头骨量，并检查唑来膦酸盐在大鼠改良 CTA 模型 (mCTA) 中的治疗效果。使用 CT 图像中的 Hounsfield 单位测量 CTA 患者的骨量。通过横切成年大鼠肩部的肩袖、肱二头肌腱和关节囊上半部来诱导 mCTA。单次皮下注射唑来膦酸后进行肱骨头的骨组织形态计量学和免疫组织化学以及小鼠肩关节炎评分（MSAS）评估。 CTA 患者的肱骨头骨量减少。在 mCTA 模型中，滑膜中的 M1 巨噬细胞增加，而唑来膦酸治疗后 M1 巨噬细胞减少。 mCTA 滑膜和关节软骨中 TNF-α、IL-1β 和 IL-6 的表达增加在唑来膦酸治疗的 mCTA 组中受到抑制。关节软骨和 MSAS 中分解代谢酶的表达显示出相似的结果。与对照 mCTA 组相比，唑来膦酸治疗的 mCTA 组软骨下骨塌陷减少，RANKL/OPG 表达比降低，破骨细胞数量受到抑制。在唑来膦酸盐治疗的 mCTA 组中，mCTA 肩部中 HMGB1 和 S100A9 增强的表达被消除。 CTA 患者的肱骨头软骨下骨减少。在 mCTA 模型中，服用唑来膦酸盐可预防塌陷和骨关节炎变化。唑来膦酸盐似乎抑制滑膜中 M1 巨噬细胞和软骨下骨中破骨细胞的数量。